2023
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial
Morita A, Strober B, Burden A, Choon S, Anadkat M, Marrakchi S, Tsai T, Gordon K, Thaçi D, Zheng M, Hu N, Haeufel T, Thoma C, Lebwohl M. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial. The Lancet 2023, 402: 1541-1551. PMID: 37738999, DOI: 10.1016/s0140-6736(23)01378-8.Peer-Reviewed Original ResearchConceptsPhysician Global Assessment scoreGPP flaresGlobal assessment scoreFlare preventionDose-response relationshipPrimary endpointAssessment scoresPhase 2b trialPustular psoriasis flarePlacebo-controlled trialReceptor monoclonal antibodyEligible study participantsQuality of lifeDose-response curveSubcutaneous placeboPlacebo groupWeek 48Pustular psoriasisPrimary outcomePsoriasis flareTreatment armsPatient groupHypersensitivity reactionsPatient morbiditySpesolimab
2019
Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients
Menter A, Cordoro KM, Davis DMR, Kroshinsky D, Paller AS, Armstrong AW, Connor C, Elewski BE, Gelfand JM, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Parra SL, Pathy AL, Farley Prater E, Rupani RN, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Elmets CA. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. Journal Of The American Academy Of Dermatology 2019, 82: 161-201. PMID: 31703821, DOI: 10.1016/j.jaad.2019.08.049.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdrenal Cortex HormonesAnthralinBiological ProductsCalcineurin InhibitorsCardiovascular DiseasesChildChild, PreschoolCoal TarComorbidityCyclosporineDermatologic AgentsDyslipidemiasEvidence-Based MedicineHumansInfantInfant, NewbornInflammatory Bowel DiseasesInsulin ResistanceMental HealthMetabolic SyndromeMethotrexateNicotinic AcidsObesityPhotochemotherapyPsoriasisRetinoidsConceptsPediatric patientsDermatology–National Psoriasis Foundation guidelinesTreatment of psoriasisImportant clinical questionsEvidence-based recommendationsJoint American AcademyPsoriasis managementInflammatory diseasesFoundation guidelinesClinical questionsPatientsAmerican AcademyPsoriasisProvider interactionsGuideline sectionsUnique physiologyGuidelinesPharmacokineticsDiseaseCareMultisystemFeasibility and Utility of the Psoriasis Symptom Inventory (PSI) in Clinical Care Settings: A Study from the International Psoriasis Council
Strober B, van de Kerkhof P, Callis Duffin K, Poulin Y, Warren R, de la Cruz C, van der Walt J, Stolshek B, Martin M, de Carvalho A. Feasibility and Utility of the Psoriasis Symptom Inventory (PSI) in Clinical Care Settings: A Study from the International Psoriasis Council. American Journal Of Clinical Dermatology 2019, 20: 699-709. PMID: 31228013, PMCID: PMC6764927, DOI: 10.1007/s40257-019-00458-2.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overClinical Decision-MakingCommunicationCross-Sectional StudiesFeasibility StudiesFemaleHumansInternational CooperationMaleMiddle AgedPatient Reported Outcome MeasuresPhysician-Patient RelationsPsoriasisQuality of LifeSeverity of Illness IndexSurveys and QuestionnairesTreatment OutcomeYoung AdultConceptsPsoriasis Symptom InventoryStatic Physician's Global AssessmentBody surface areaPsoriasis-affected body surface areaSymptom InventoryPatient-reported outcome measuresPatient treatment prioritiesPhysician global assessmentPatient-physician communicationClinical care settingsInternational Psoriasis CouncilPSI total scorePatient-physician relationshipMild psoriasisPsoriasis signsSevere psoriasisUntreated patientsModerate psoriasisDermatology clinicPsoriasis severityPatient visitsSame visitTreatment decisionsCare settingsOutcome measures
2018
Benefit–risk profile of tofacitinib in patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis across six clinical trials
Strober B, Gottlieb A, Kerkhof P, Puig L, Bachelez H, Chouela E, Imafuku S, Thaçi D, Tan H, Valdez H, Gupta P, Kaur M, Frajzyngier V, Wolk R. Benefit–risk profile of tofacitinib in patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis across six clinical trials. British Journal Of Dermatology 2018, 180: 67-75. PMID: 30188571, PMCID: PMC7379291, DOI: 10.1111/bjd.17149.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdolescentAdultAgedAged, 80 and overChronic DiseaseDose-Response Relationship, DrugFemaleHumansMaleMiddle AgedPiperidinesProtein Kinase InhibitorsPsoriasisPyrimidinesPyrrolesQuality of LifeRandomized Controlled Trials as TopicRisk AssessmentSeverity of Illness IndexYoung AdultConceptsSevere chronic plaque psoriasisChronic plaque psoriasisEfficacy end pointBenefit-risk profileSevere psoriasisPlaque psoriasisWeek 16Dermatology Life Quality Index scoresLong-term extension studyOral Janus kinase inhibitorGlobal assessmentLife Quality Index scoresEnd pointDepression Scale depression scorePhysician global assessmentImproved patients' qualitySystemic psoriasis therapiesJanus kinase inhibitorQuality Index scoresTofacitinib 5Tofacitinib exposurePsoriasis AreaSystemic treatmentTofacitinib treatmentPatients' quality
2017
Clinical trials: Kids are not just little people
Naka F, Strober B, Shahriari M. Clinical trials: Kids are not just little people. Clinics In Dermatology 2017, 35: 583-593. PMID: 29191349, DOI: 10.1016/j.clindermatol.2017.08.008.Peer-Reviewed Original Research
2016
Psoriasis in adults and children: Kids are not just little people
de Moll EH, Chang MW, Strober B. Psoriasis in adults and children: Kids are not just little people. Clinics In Dermatology 2016, 34: 717-723. PMID: 27968931, DOI: 10.1016/j.clindermatol.2016.07.006.Peer-Reviewed Original ResearchConceptsPediatric psoriasisPediatric populationLimited therapeutic armamentariumPrimary care providersCommon skin disorderAdult psoriasisYounger patientsTherapeutic armamentariumTreatment optionsSchool-aged childrenAppropriate treatmentCare providersPsoriasisSkin disordersIncurable diseasePsychosocial ramificationsPatientsAge childrenChildrenInherent risksPresentationChronicInfantsTherapyPopulationTreatment of Moderate to Severe Pediatric Psoriasis: A Retrospective Case Series
Klufas D, Wald J, Strober B. Treatment of Moderate to Severe Pediatric Psoriasis: A Retrospective Case Series. Pediatric Dermatology 2016, 33: 142-149. PMID: 26871417, DOI: 10.1111/pde.12782.Peer-Reviewed Original ResearchConceptsSevere pediatric psoriasisRetrospective case seriesPediatric psoriasisCase seriesSevere psoriasisSystemic therapySide effectsDisease responseSimilar side effect profilePhysician Global Assessment scaleComprehensive safety profileSmall sample sizeSingle referral centerSubjective side effectsSide effect profileSafety of treatmentMultiple treatment optionsAdverse event occurrenceComparison of efficacyGlobal Assessment ScalePaucity of dataAdult psoriasisImmunomodulating therapiesAdverse eventsReferral center
2015
Psychometric validation of the Psoriasis Symptom Diary using Phase III study data from patients with chronic plaque psoriasis
Strober B, Zhao Y, Tran MH, Gnanasakthy A, Nyirady J, Papavassilis C, Nelson LM, McLeod LD, Mordin M, Gottlieb AB, Elewski BE, Lebwohl M. Psychometric validation of the Psoriasis Symptom Diary using Phase III study data from patients with chronic plaque psoriasis. International Journal Of Dermatology 2015, 55: e147-e155. PMID: 26518255, DOI: 10.1111/ijd.13117.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedClinical Trials, Phase III as TopicDermatologic AgentsFemaleHumansMaleMiddle AgedMulticenter Studies as TopicPatient Reported Outcome MeasuresPsoriasisPsychometricsQuality of LifeRandomized Controlled Trials as TopicReproducibility of ResultsSelf ReportSeverity of Illness IndexSurveys and QuestionnairesSymptom AssessmentYoung AdultConceptsDermatology Life Quality IndexChronic plaque psoriasisInvestigator's Global AssessmentPhase III studyPlaque psoriasisIII studySymptom diarySevere chronic plaque psoriasisMulticenter phase III studyGlobal assessmentSafety of secukinumabSevere plaque psoriasisPatient Global ImpressionPercentage of respondersHealth Status QuestionnaireLife Quality IndexHigh intraclass coefficientsPlacebo armPsoriasis AreaTest-retest reliabilityWeek 12Global ImpressionStatus QuestionnaireTreatment decisionsMean differencePhase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, Papp K, Spelman L, Toth D, Kerdel F, Armstrong AW, Stingl G, Kimball AB, Bachelez H, Wu JJ, Crowley J, Langley RG, Blicharski T, Paul C, Lacour JP, Tyring S, Kircik L, Chimenti S, Callis Duffin K, Bagel J, Koo J, Aras G, Li J, Song W, Milmont CE, Shi Y, Erondu N, Klekotka P, Kotzin B, Nirula A. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. New England Journal Of Medicine 2015, 373: 1318-1328. PMID: 26422722, DOI: 10.1056/nejmoa1503824.Peer-Reviewed Original ResearchConceptsPASI 100 response ratesGlobal assessment scoreWeek 12Response rateSevere psoriasisStatic Physician's Global Assessment scorePASI 75 response ratesPhysician Global Assessment scoreRates of neutropeniaSerious infectious episodesPhase 3 studySignificant clinical improvementSeverity Index scoreTreatment of psoriasisEarly clinical studiesAMAGINE-2Brodalumab treatmentSPGA scoreInfectious episodesWeek 52Clinical improvementMaintenance dosePASI scorePsoriasis AreaBrodalumabThe Use of Methotrexate, Alone or in Combination With Other Therapies, for the Treatment of Palmoplantar Psoriasis.
Wald J, Klufas D, Strober B. The Use of Methotrexate, Alone or in Combination With Other Therapies, for the Treatment of Palmoplantar Psoriasis. Journal Of Drugs In Dermatology 2015, 14: 888-92. PMID: 26267735.Peer-Reviewed Original ResearchMeSH KeywordsAdalimumabAdolescentAdultAgedAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalCyclosporineDermatologic AgentsDrug Therapy, CombinationEtanerceptFemaleFoot DermatosesHand DermatosesHumansImmunosuppressive AgentsInfliximabMaleMethotrexateMiddle AgedMycophenolic AcidPsoriasisSeverity of Illness IndexThalidomideUstekinumabYoung Adult
2013
Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment
Strober B, Buonanno M, Clark J, Kawabata T, Tan H, Wolk R, Valdez H, Langley R, Harness J, Menter A, Papp K. Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment. British Journal Of Dermatology 2013, 169: 992-999. PMID: 23855761, DOI: 10.1111/bjd.12517.Peer-Reviewed Original ResearchConceptsPhase IIb trialJanus kinase inhibitorDose-dependent decreaseTofacitinib 2IIb trialCell countNatural killer cell countsReversible dose-dependent decreaseSevere chronic plaque psoriasisHaematological parametersKinase inhibitorsB-cell countsChronic plaque psoriasisEffects of tofacitinibShort-term administrationClear dose-dependent effectTreatment of psoriasisRed blood cell countBlood cell countWhite blood cellsDose-dependent effectDose-dependent changesHaematology dataPlaque psoriasisLymphocyte countThe Psoriasis Symptom Diary: development and content validity of a novel patient‐reported outcome instrument
Lebwohl M, Swensen A, Nyirady J, Kim E, Gwaltney C, Strober B. The Psoriasis Symptom Diary: development and content validity of a novel patient‐reported outcome instrument. International Journal Of Dermatology 2013, 53: 714-722. PMID: 23557000, DOI: 10.1111/j.1365-4632.2012.05798.x.Peer-Reviewed Original ResearchMeSH KeywordsAdaptation, PhysiologicalAdaptation, PsychologicalAdolescentAdultAge FactorsAgedCohort StudiesFemaleHumansMaleMiddle AgedObserver VariationPsoriasisPsychometricsQuality of LifeSelf ReportSeverity of Illness IndexSex FactorsSickness Impact ProfileSurveys and QuestionnairesTreatment OutcomeYoung AdultConceptsSymptom diaryPatient experienceNovel patient-reported outcome instrumentContent validityPatient-reported outcome instrumentsPsoriasis-related symptomsQuantitative psychometric testingChronic plaque psoriasisImpact of symptomsQualitative patient interviewsVariety of symptomsPatient's daily lifeNew PRO instrumentAppearance of plaquesPlaque psoriasisEfficacy endpointPsoriasis treatmentPatient interviewsClinical trialsNew patientsPatient understandingOutcome instrumentsImportant symptomKey patient experiencesPRO instrumentsTopical Chemotherapy in Cutaneous T-cell Lymphoma: Positive Results of a Randomized, Controlled, Multicenter Trial Testing the Efficacy and Safety of a Novel Mechlorethamine, 0.02%, Gel in Mycosis Fungoides
Lessin S, Duvic M, Guitart J, Pandya A, Strober B, Olsen E, Hull C, Knobler E, Rook A, Kim E, Naylor M, Adelson D, Kimball A, Wood G, Sundram U, Wu H, Kim Y. Topical Chemotherapy in Cutaneous T-cell Lymphoma: Positive Results of a Randomized, Controlled, Multicenter Trial Testing the Efficacy and Safety of a Novel Mechlorethamine, 0.02%, Gel in Mycosis Fungoides. JAMA Dermatology 2013, 149: 25-32. PMID: 23069814, PMCID: PMC3662469, DOI: 10.1001/2013.jamadermatol.541.Peer-Reviewed Original ResearchConceptsIndex Lesion SeverityClinical end pointsMycosis fungoidesResponse rateMechlorethamine gelAdverse eventsMulticenter trialTreatment armsLesion severityDrug-related serious adverse eventsSeverity-Weighted Assessment ToolPrimary clinical end pointCutaneous T-cell lymphomaEnd pointSecondary clinical end pointsIIA mycosis fungoidesSerious adverse eventsSubset of patientsTreatment of patientsSerum drug levelsT-cell lymphomaComposite assessmentCarmustine therapyStudy medicationTopical mechlorethamine
2012
Psoriasis and Down syndrome: a report of three cases and a potential pathophysiologic link.
Marmon S, De Souza A, Strober B. Psoriasis and Down syndrome: a report of three cases and a potential pathophysiologic link. Dermatology Online Journal 2012, 18: 13. PMID: 22747937, DOI: 10.5070/d305m5f4bx.Peer-Reviewed Original ResearchConceptsDown syndromeSerum levelsIFN-gammaChronic plaque psoriasisPotential pathophysiologic linksHigher serum levelsCases of patientsProduction of cytokinesTumor necrosis factorTh1 lineage cellsPathophysiologic linkPlaque psoriasisTh17 cellsTh17 pathwayPatient populationIL-2Healthy controlsNecrosis factorGreater prevalencePsoriasisSyndromeIFN systemPatientsLineage cellsCells
2011
Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events: A Meta-analysis of Randomized Controlled Trials
Ryan C, Leonardi C, Krueger J, Kimball A, Strober B, Gordon K, Langley R, de Lemos J, Daoud Y, Blankenship D, Kazi S, Kaplan D, Friedewald V, Menter A. Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events: A Meta-analysis of Randomized Controlled Trials. JAMA 2011, 306: 864-871. PMID: 21862748, DOI: 10.1001/jama.2011.1211.Peer-Reviewed Original ResearchMeSH KeywordsAdalimumabAdolescentAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedCardiovascular DiseasesDouble-Blind MethodEtanerceptHumansImmunoglobulin GImmunologic FactorsInfliximabInterleukin-12Interleukin-23Middle AgedMyocardial InfarctionPlacebosPsoriasisRandomized Controlled Trials as TopicReceptors, Tumor Necrosis FactorRiskStrokeTumor Necrosis Factor-alphaUstekinumabYoung AdultConceptsMajor adverse cardiovascular eventsChronic plaque psoriasisAnti-IL-12/23 agentsPlacebo-controlled phaseΑ agentsCardiovascular eventsPlaque psoriasisBiologic therapyControlled TrialsAnti-tumor necrosis factor α agentsRate of MACEAnti-IL-12/ILMantel-Haenszel fixed-effect methodAnti-IL-12/23 therapyAdverse cardiovascular eventsCochrane Central RegisterComposite end pointAbsolute risk differencePrimary outcome measureRandomized Controlled TrialsSignificant differencesCardiovascular deathMonotherapy studiesΑ treatmentCentral Register
2009
Alefacept for Severe Alopecia Areata: A Randomized, Double-blind, Placebo-Controlled Study
Strober B, Menon K, McMichael A, Hordinsky M, Krueger G, Panko J, Siu K, Lustgarten J, Ross E, Shapiro J. Alefacept for Severe Alopecia Areata: A Randomized, Double-blind, Placebo-Controlled Study. JAMA Dermatology 2009, 145: 1262-1266. PMID: 19917955, DOI: 10.1001/archdermatol.2009.264.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAdolescentAdultAgedAlefaceptAlopecia AreataDermatologic AgentsDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleFemaleFollow-Up StudiesHumansInjections, IntramuscularMaleMiddle AgedNew York CityProbabilityRecombinant Fusion ProteinsRisk AssessmentSeverity of Illness IndexStatistics, NonparametricTreatment OutcomeYoung AdultConceptsSevere alopecia areataAlopecia areataPlacebo-controlled clinical trialEfficacy of alefaceptPlacebo-receiving groupSevere plaque psoriasisMain outcome measuresPlaque psoriasisPrevious therapyAlopecia ToolClinical trialsAlefaceptOutcome measuresUS FoodDrug AdministrationConsecutive weeksBiologic inhibitorsScalp hairAreataTreatmentWeeksSignificant improvementMulticenterPlaceboPsoriasis
2007
Efalizumab for the treatment of refractory hidradenitis suppurativa
Strober B, Kim C, Siu K. Efalizumab for the treatment of refractory hidradenitis suppurativa. Journal Of The American Academy Of Dermatology 2007, 57: 1090-1091. PMID: 18021852, DOI: 10.1016/j.jaad.2007.07.032.Peer-Reviewed Original Research
2006
A prospective randomized clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitis
Belsito D, Wilson D, Warshaw E, Fowler J, Ehrlich A, Anderson B, Strober B, Willetts J, Rutledge E. A prospective randomized clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitis. Journal Of The American Academy Of Dermatology 2006, 55: 40-46. PMID: 16781290, DOI: 10.1016/j.jaad.2006.03.025.Peer-Reviewed Original ResearchConceptsAllergic contact dermatitisNickel-induced allergic contact dermatitisTacrolimus ointmentAdverse eventsContact dermatitisSymptoms of ACDGlobal assessmentChronic allergic contact dermatitisPhysician global assessmentTacrolimus ointment 0.1Pruritus scoreClinical trialsPruritus reductionDay 8TacrolimusDermatitisInner aspectPatientsOintmentSignsTolerabilityArmSymptomsAgentsTrialsUse of etanercept for psoriatic arthritis in the dermatology clinic: The Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study
Gottlieb A, Kircik L, Eisen D, Jackson J, Boh E, Strober B, Frankel E, Xia H, Stevens S. Use of etanercept for psoriatic arthritis in the dermatology clinic: The Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study. Journal Of Dermatological Treatment 2006, 17: 343-352. PMID: 17853307, DOI: 10.1080/09546630600967166.Peer-Reviewed Original ResearchConceptsPsoriatic arthritisDermatology clinicBody surface area involvementGlobal assessmentTolerability of etanerceptPatient global assessmentPhysician global assessmentSerious adverse eventsUse of etanerceptSurface area involvementActive psoriatic arthritisWeeks of treatmentBody surface areaEtanercept treatmentExperience diagnosingEtanercept therapyPlaque psoriasisAdverse eventsJoint painArea involvementJoint diseaseDisease scorePatientsArthritisPsoriasis
2005
Off-Label Dermatologic Uses of Anti-TNF-a Therapies
Alexis A, Strober B. Off-Label Dermatologic Uses of Anti-TNF-a Therapies. Journal Of Cutaneous Medicine And Surgery 2005, 9: 296-302. PMID: 16699906, DOI: 10.1007/s10227-005-0110-7.Peer-Reviewed Original ResearchMeSH KeywordsAdalimumabAdolescentAdultAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedArthritis, PsoriaticChildChild, PreschoolChi-Square DistributionEtanerceptFemaleHumansImmunoglobulin GInfantInfliximabMalePsoriasisRandomized Controlled Trials as TopicReceptors, Tumor Necrosis FactorSkin DiseasesTime FactorsTumor Necrosis Factor-alphaConceptsDermatologic usesTNF inhibitorsDermatologic diseasesSneddon-Wilkinson diseaseInflammatory skin diseaseSmall case seriesNecrobiosis lipoidica diabeticorumPityriasis rubra pilarisMethodsA MEDLINE searchNumerous inflammatory skin diseasesIndividual case reportsApthous stomatitisBehçet's diseaseEosinophilic fasciitisSAPHO syndromeCase seriesCicatricial pemphigoidCrohn's diseaseMulticentric reticulohistiocytosisImmunomodulatory roleProinflammatory cytokinesCase reportLabel useMEDLINE searchSkin diseases